Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy (PRINT)
Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy
Study Design & Objectives:
Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with a clinical follow-up between 12 and 14 weeks.
To determine the performances of the RA-INF-Dx blood test intended to aid in the identification of patients with rheumatoid arthritis who are unlikely to show an initial response to infliximab and methotrexate combination therapy evaluated according to EULAR response criteria.
Ancillary study objective:
To constitute a biocollection of samples associated with all clinical and biological data collected at inclusion and at the evaluation visit.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Description détaillée
The RA-INF-Dx test is a non invasive in vitro blood test intended to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
The RA-INF-Dx test is indicated for use in patients:
- 18 years of age or older,
- Eligible for a first line biologic therapy with infliximab. The RA-INF-Dx test is indicated for use by rheumatologists as a biological basis for guiding infliximab treatment prior to its initiation.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Contacts et emplacements
Lieux d'étude
-
-
-
Mississauga - Chow, Canada
- Location n°31
-
Ontario, Canada
- Location n°36
-
Rimouski, Canada
- Location n°34
-
Saskatchewan, Canada
- Location n°33
-
Toronto, Canada
- Location n°35
-
-
-
-
-
Malaga, Espagne
- Location n°3
-
Oviedo, Espagne
- Location n°5
-
-
-
-
-
Amiens, France
- Location n°41
-
Bobigny, France
- Location n°13
-
Dreux, France
- Location n°39
-
Grenoble, France
- Location n°14
-
Meaux, France
- Location n°40
-
Paris, France
- Location n°25
-
Paris (Hop Bichat), France
- Location n°37
-
Strasbourg, France
- Location n°38
-
-
-
-
-
Budapest, Hongrie
- Location n°6
-
Budapest, Hongrie
- Location n°8
-
Debrecen, Hongrie
- Location n°7
-
Eger, Hongrie
- Location n°10
-
Kistarcsa, Hongrie
- Location n°9
-
-
-
-
-
Messina, Italie
- Location n°15
-
Milano, Italie
- Location n°16
-
Pisa, Italie
- Location n°17
-
-
-
-
-
Kaunas, Lituanie
- Location n°27
-
Klaipeda, Lituanie
- Location n°29
-
Panevezys, Lituanie
- Location n°30
-
Vilnius, Lituanie
- Location n°28
-
-
-
-
-
Bucharest, Roumanie
- Location n° 19
-
Bucharest, Roumanie
- Location n°20
-
Bucharest, Roumanie
- Location n°22
-
Bucharest, Roumanie
- Location n°23
-
Cluj Napoca, Roumanie
- Location n°21
-
Iasi, Roumanie
- Location n°24
-
Iasi, Roumanie
- Location n°26
-
Timisoara, Roumanie
- Location n°18
-
-
-
-
-
Banska Bystrica, Slovaquie
- Location n°12
-
Piestany, Slovaquie
- Location n°11
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis
Patient with a confirmed Rheumatoid Arthritis according the American College of Rheumatology (ACR) classification criteria.
Disease Activity
Patient with a DAS28 greater than 3.2.
Treatment
- Patient eligible for a first line TNFα blocking agent treatment with infliximab according to the "Summary of Product Characteristics",
- Patient refractory to treatment with at least one classical DMARDs (one of which has to be MTX) prescribed according to the international recommendations, i.e. for at least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with doses which must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy (patients may be included if they have undergone a wash-out period using cholestyramine or equivalent subsequent to leflunomide treatment),
Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy,
Other criteria
- Patient (male or female) at 18 years of age or older at inclusion,
- Negative β-HCG pregnancy test, when appropriate according to the patient's age and contraceptive method,
- Informed consent signed.
Exclusion Criteria:
- Patient having received previous courses of other biologic therapy (TNF blocking agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in development),
- Patient non eligible to infliximab therapy according to the "Summary of Product Characteristics",
- Patient with clinically significant, severe and uncontrolled infectious diseases,
- Patient with symptoms of a significant somatic or psychiatric/mental illness,
- Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),
- Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic, gastro-intestinal conditions, which, in the opinion of the investigator, may interfere with the study,
- Pregnancy,
- Patient that is participating in a clinical trial or that participated in a previous one within 10 weeks prior to study entry.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
|---|
|
a single group of patients -200 expected
polyarthrite rhumatoid patients
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To determine the performances of the RA-INF-Dx test to aid in the identification of patients with RA who are unlikely to show an initial response to infliximab and methotrexate combination therapy.
Délai: Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
Statistical relationship between the RA-INF-Dx blood test results and the non-response (evaluated according to EULAR criteria) to infliximab and methotrexate combination therapy will be analyzed.
|
Performed at inclusion : blood samples will be taken before the infliximab infusion.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Non-response to infliximab and methotrexate combination therapy based on American College of Rheumatology (ACR) criteria
Délai: at the time of the first response evaluation (between the 12th and the 14th week)
|
A statistical analysis will be performed in order to evaluate the predictive performances of the test validated in the study primary objective in relation to the non-response to infliximab and methotrexate combination therapy evaluated according to ACR criteria.
|
at the time of the first response evaluation (between the 12th and the 14th week)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Sara MARSAL, MD, University Hospital Val d'Hebron (Barcelona, Spain)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2010-A01046-33
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .